financetom
Business
financetom
/
Business
/
Canadian Banks' U.S. Regulatory Filings Show "Weak Margins And Tepid Loan Growth"
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canadian Banks' U.S. Regulatory Filings Show "Weak Margins And Tepid Loan Growth"
May 2, 2024 11:51 AM

02:35 PM EDT, 05/02/2024 (MT Newswires) -- Quarterly financial filings with the Fed (Call Reports) by Canadian banks with U.S. subsidiaries have just become available.

National Bank highlights the following takeaways:

BMO, CIBC and TD reported a similar decline in NIM (down 4-5 bps Q/Q). RBC recorded the most significant decline in NIM (down 11 bps Q/Q), with interest income falling 3% Q/Q and deposit costs increasing 2% Q/Q.

TD and CIBC saw sequential loan growth of 1% Q/Q and 2% Q/Q (mainly driven by its commercial loan portfolios), while loan growth was down 1% Q/Q for BMO and RBC. TD's 1% growth was led by commercial (+2% Q/Q), which offset a seasonal decline in card loans (down 6% Q/Q).

TD reported a US$450 million regulatory provision. The FDIC has also assessed an additional charge related to last year's bank crisis, estimated at roughly 15% of last quarter's figure (~mid-single-digit impact on NIX). Banks are expected to treat these items as "one-time" expenses.

CIBC's results included the largest sequential change in provisioning rate, at 27 bps Q/Q. Analyst Gabriel Dechaine attributes this performance largely to CECL volatility. In terms of non-accrual loans, BMO and TD reported a ~20% increase in this line item, while CIBC saw a 36% increase due to a doubling in C&I non-accrual loans.

Excluding the AOCI "opt-out", all U.S. operations of Canadian banks have CET 1 and leverage ratios solidly above current regulatory minimums of ~7-8% and ~4%, respectively. Additionally, all banks saw a significant Q/Q improvement in pro forma CET 1 ratios and were up on average ~40 bps Q/Q led by TD (up 80 bps) and RBC (up 60 bps).

Price: 123.00, Change: -0.34, Percent Change: -0.28

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Domino's Pizza Poised to Report 'Solid' Results, 'Modest Beat' in Q3, Morgan Stanley Says
Domino's Pizza Poised to Report 'Solid' Results, 'Modest Beat' in Q3, Morgan Stanley Says
Oct 8, 2025
11:06 AM EDT, 10/08/2025 (MT Newswires) -- Domino's Pizza (DPZ) is poised to report a solid Q3 with a modest beat of Street expectations, Morgan Stanley said in a Wednesday note. The company remains partly insulated from burger wars in the US and is fairly resilient in overseas markets, given its good value proposition and own product drivers, according to...
Airlines brace for third day of flight delays as shutdown persists
Airlines brace for third day of flight delays as shutdown persists
Oct 8, 2025
BALTIMORE (Reuters) -Major U.S. airlines are bracing for a third straight day of delays on Wednesday as the U.S. Federal Aviation Administration faces higher-than-normal staffing issues for air traffic controllers as the stalemate over funding the government continues. There were nearly 10,000 flight delays in total on Monday and Tuesday, with many tied to the FAA slowing flights because of...
Major Boeing customer Ryanair sees 737 production hitting 48 per month by April
Major Boeing customer Ryanair sees 737 production hitting 48 per month by April
Oct 8, 2025
MADRID, Oct 8 (Reuters) - Major Boeing customer Ryanair said on Wednesday it was confident the U.S. planemaker would get permission to boost the monthly production rate of its flagship 737 model to 42 in October and then 48 by March or April next year. The Irish airline, Boeing's largest European customer, has had to repeatedly cut growth forecasts due...
Incyte May Face Long-Term Revenue Erosion on Generic Competition, Oppenheimer Says
Incyte May Face Long-Term Revenue Erosion on Generic Competition, Oppenheimer Says
Oct 8, 2025
11:04 AM EDT, 10/08/2025 (MT Newswires) -- Incyte ( INCY ) faces near certain revenue erosion over the long term as generic competition for its blood-disease drug Jakafi looms before the end of the decade, Oppenheimer said Tuesday in a report. Based on the Jakafi patent cliff, consensus revenue estimates reflect a steep decline in 2029 with almost $4 billion...
Copyright 2023-2026 - www.financetom.com All Rights Reserved